Literature DB >> 8956720

Intravenous immunoglobulin in the Guillain-Barré syndrome. Products with low IgA content may be used in patients with total IgA deficiency.

S Misbah.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8956720      PMCID： PMC2352877          DOI： 10.1136/bmj.313.7069.1400

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  4 in total

Review 1.  The use of intravenous immune globulin in immunodeficiency diseases.

Authors:  R H Buckley; R I Schiff
Journal:  N Engl J Med       Date:  1991-07-11       Impact factor: 91.245

2.  Intravenous IgG in Guillain-Barré syndrome.

Authors:  R A Hughes
Journal:  BMJ       Date:  1996-08-17

3.  Long-term use of IgA-depleted intravenous immunoglobulin in immunodeficient subjects with anti-IgA antibodies.

Authors:  C Cunningham-Rundles; Z Zhou; S Mankarious; S Courter
Journal:  J Clin Immunol       Date:  1993-07       Impact factor: 8.317

4.  Acute renal failure resulting from intravenous immunoglobulin therapy.

Authors:  E Tan; M Hajinazarian; W Bay; J Neff; J R Mendell
Journal:  Arch Neurol       Date:  1993-02
  4 in total
  2 in total

Review 1.  Evidence for the use of intravenous immunoglobulins--a review of the literature.

Authors:  Shaye Kivity; Uriel Katz; Natalie Daniel; Udi Nussinovitch; Neophytos Papageorgiou; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

2.  In vitro and in vivo properties differ among liquid intravenous immunoglobulin preparations.

Authors:  F Dhainaut; P-O Guillaumat; H Dib; G Perret; A Sauger; C de Coupade; M Beaudet; M Elzaabi; L Mouthon
Journal:  Vox Sang       Date:  2012-09-25       Impact factor: 2.144
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.